JPRN-jRCT2080220259未知3 期
Open Label, Randomised, Parallel Group, Multicentre, Ph III Study To Assess Efficacy, Safety & Tolerability Of Gefitinib (IRESSA) Versus Carboplatin/Paclitaxel DC As 1st-Line Treatment In Selected Patients With Stage IIIB / IV NSCLC In Asia
适应症
试验速览
- 阶段
- 3 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
- •Inclusion Criteria:
- •- Locally advanced Stage IIIB not amenable to local therapy or Stage IV (metastatic) NSCLC with adenocarcinoma histology.
- •- Never smokers or light ex-smokers (ceased smoking at least 15 years before Day 1 of study treatment and 10 pack-years or fewer).
排除标准
- •- Had prior chemotherapy, biological (including targeted therapies such as EGFR and vascular epidermal growth factor (VEGF) inhibitors) or immunological therapy.
- •- Pre-existing idiopathic pulmonary fibrosis evidence by CT scan at baseline.
研究者
相似试验
进行中（未招募）
不适用
Open label, randomized, parallel group, multicenter study to investigate the efficacy and safety of once-weekly (reduced administration frequency) NeoRecormon® therapy versus thrice weekly NeoRecormon® therapy in anaemic cancer patients with solid tumours receiving chemotherapy (or scheduled to receive chemotherapy)Anaemia in breast tumour subjectsEUCTR2006-002119-28-EEF. Hoffmann-La Roche Ltd.280
进行中（未招募）
不适用
Open label, randomized, parallel group, multicenter study to investigate the efficacy and safety of once-weekly (reduced administration frequency) NeoRecormon® therapy versus thrice weekly NeoRecormon® therapy in anaemic cancer patients with solid tumours receiving chemotherapy (or scheduled to receive chemotherapy)EUCTR2006-002119-28-CZF. Hoffmann-La Roche Ltd.280
进行中（未招募）
不适用
Open label, randomized, parallel group, multicenter study to investigate the efficacy and safety of once-weekly (reduced administration frequency) NeoRecormon® therapy versus thrice weekly NeoRecormon® therapy in anaemic cancer patients with solid tumours receiving chemotherapy (or scheduled to receive chemotherapy)Anaemia in breast tumour subjectsEUCTR2006-002119-28-LVF. Hoffmann-La Roche Ltd.280
进行中（未招募）
1 期
Open label, randomized, parallel group, multicenter study to investigate the efficacy and safety of once-weekly (reduced administration frequency) NeoRecormon® therapy versus thrice weekly NeoRecormon® therapy in anaemic cancer patients with solid tumours receiving chemotherapy (or scheduled to receive chemotherapy)EUCTR2006-002119-28-GBF. Hoffmann-La Roche Ltd.280
进行中（未招募）
不适用
Open label, randomized, parallel group, multicenter study to investigate the efficacy and safety of once-weekly (reduced administration frequency) NeoRecormon® therapy versus thrice weekly NeoRecormon® therapy in anaemic cancer patients with solid tumours receiving chemotherapy (or scheduled to receive chemotherapy)EUCTR2006-002119-28-ATF. Hoffmann-La Roche Ltd.280